RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06383767, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically and/or cytologically confirmed HR+/HER2- breast cancer who had failed at least one line of systemic chemotherapy in metastatic settings;

    Inclusion criterion 3

  3. Received chemotherapy, targeted therapy, immunotherapy, interventional therapy or other systemic anti-cancer therapie within 4 weeks before the first investigational product administration;

    Exclusion criterion 1

    Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1;

    Exclusion criterion 2

    Received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ;

    Exclusion criterion 3

    Prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy, or prior TROP2 targeted therapy, or use of any investigational anti-cancer drug within 28 days or 5 half-lives before the first investigational product administration;

    Exclusion criterion 4

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;

    Inclusion criterion 6

  5. Patients with at least one measurable lesion per RECIST 1.1 criteria;

    Inclusion criterion 5

  6. Patients with Primary CNS malignancy;or patients with other malignancies within 3 years prior to the first dose;

    Exclusion criterion 8

    Human Immunodeficiency Virus (HIV) infection;

    Exclusion criterion 12

  7. Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 180 days after the last dose.

    Inclusion criterion 9

    Pregnant or lactating women.

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06383767, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Individuals able to understand and give written informed consent.
  • Males or females aged ≥ 18 years ;
  • Histologically and/or cytologically confirmed HR+/HER2- breast cancer who had failed at least one line of systemic chemotherapy in metastatic settings;
  • Patients who are eligible for a chemotherapy regimen in the control group;
  • Patients with at least one measurable lesion per RECIST 1.1 criteria;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;
  • Expected survival ≥ 12 weeks;
  • Patients with adequate organ and bone marrow function;
  • Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 180 days after the last dose.

Exclusion Criteria:

  • Received chemotherapy, targeted therapy, immunotherapy, interventional therapy or other systemic anti-cancer therapie within 4 weeks before the first investigational product administration;
  • Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1;
  • Received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ;
  • Prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy, or prior TROP2 targeted therapy, or use of any investigational anti-cancer drug within 28 days or 5 half-lives before the first investigational product administration;
  • New thromboembolic events, intestinal obstruction, gastrointestinal bleeding or perforation within 6 months;
  • Uncontrolled systemic bacterial, viral or fungal infections;
  • Subjects with symptomatic or untreated CNS metastases, or those requiring ongoing treatment for CNS metastases;
  • Patients with Primary CNS malignancy;or patients with other malignancies within 3 years prior to the first dose;
  • Patients with uncontrollable systemic diseases;
  • Patients with gastrointestinal diseases (such as chronic gastritis, chronic enteritis or gastric ulcers), or with a previous history of severe or chronic diarrhea;
  • Subjects with clinically significant cardiovascular disease;
  • Human Immunodeficiency Virus (HIV) infection;
  • Active hepatitis B or hepatitis C;
  • Known immediate or delayed hypersensitivity reaction to irinotecan or other camptocampin derivatives such as topotecan or to have had grade ≥3 gastrointestinal reactions associated with irinotecan, or allergies, or to any investigational drug or excipient ingredient;
  • Pregnant or lactating women.

Quoted from ClinicalTrials.gov, NCT06383767, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06383767, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06383767